TAM KANG: Open Payments
NPI 1407250442 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$648 in 32 payments from 13 companies in 2025. Trend: 2023 $462 · 2024 $577 · 2025 $648
Food & beverage: $648
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 8 | $160 |
| Lilly USA, LLC | 6 | $96 |
| Sumitomo Pharma America, Inc. | 2 | $62 |
| PFIZER INC. | 3 | $60 |
| Janssen Pharmaceuticals, Inc | 2 | $53 |
| Novo Nordisk Inc | 3 | $49 |
| Exact Sciences Corporation | 2 | $44 |
| SI-BONE, INC. | 1 | $28 |
| GlaxoSmithKline, LLC. | 1 | $28 |
| INOGEN, INC. | 1 | $24 |
Products named: Veozah, MOUNJARO, GEMTESA, PREVNAR 20, SPRAVATO, Wegovy, TRELEGY ELLIPTA, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH.
Industry payments across TX — which companies pay providers there.
